Results 221 to 230 of about 44,899 (264)

Understanding CYP2D6 interactions

Drug Discovery Today, 2009
Owing to the polymorphic nature of CYP2D6, clinically significant issues can arise when drugs rely on that enzyme either for clearance, or metabolism to an active metabolite. Available screening methods to determine if the compound is likely to cause drug-drug interactions, or is likely to be a victim of inhibition of CYP2D6 by other compounds will be ...
Marcel J, de Groot, Florian, Wakenhut, Gavin, Whitlock, Ruth, Hyland   +3 more
openaire   +2 more sources

Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors

Journal of Neural Transmission, 2014
The cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of most antidepressants. Comedication with a potent CYP2D6 inhibitor can convert patients with extensive metabolizer (EM) or ultra-rapid metabolizer (UM) genotypes into poor metabolizer (PM) phenotypes.
F, Gressier, C, Verstuyft, P, Hardy, L, Becquemont, E, Corruble   +4 more
openaire   +2 more sources

CYP2D6*36 GENE ARRANGEMENTS WITHIN THE CYP2D6 LOCUS: ASSOCIATION OF CYP2D6*36 WITH POOR METABOLIZER STATUS

Drug Metabolism and Disposition, 2006
Unexplained cases of CYP2D6 genotype/phenotype discordance continue to be discovered. In previous studies, several African Americans with a poor metabolizer phenotype carried the reduced function CYP2D6*10 allele in combination with a nonfunctional allele.
Andrea, Gaedigk, L Dianne, Bradford, Sarah W, Alander, J Steven, Leeder   +3 more
openaire   +2 more sources

Genotyping of CYP2D6 in Parkinsons's Disease

cclm, 2000
Abstract Parkinson's disease is characterized by progressive degradation of dopaminergic neurons. Cytochrome P450 CYP2D6 enzyme is one of the most investigated and highly polymorphic isoforms, which metabolizes many drugs and is also involved in the metabolism of dopamine.
Gergorec-Koršić, Marta, Šimundić, Ana-Maria, Topić, Elizabeta, Štefanović, Mario, KORŠIĆ, MARTA   +4 more
openaire   +3 more sources

Novel Structure of the CYP2D6 Gene that Confuses Genotyping for the CYP2D6*5 Allele

Drug Metabolism and Pharmacokinetics, 2005
We encountered DNA samples which showed a positive product using a long PCR-based method for the detection of CYP2D6*5, indicating deletion of the entire CYP2D6 gene, but the samples did not show a band related to CYP2D6*5 in either XbaI- or EcoRI-RFLP analysis. To achieve genotyping with accuracy, we performed a further genetic analysis to clarify the
Tsuyoshi, Fukuda, Hiromi, Maune, Yuka, Ikenaga, Masakazu, Naohara, Kazuhiro, Fukuda, Junichi, Azuma   +5 more
openaire   +2 more sources

Implementation of CYP2D6 genotyping in psychiatry

Expert Opinion on Drug Metabolism & Toxicology, 2009
Response to pharmacotherapy is subject to large inter-individual variation. Most medicine is metabolised by CYP450 enzymes, including CYP2D6. CYP2D6 activity is determined substantially by the genetic composition. Polymorphisms of CYP2D6 are associated with inadequate response on treatment with psychotropics. The large number of polymorphisms of CYP2D6
Harriët M, Loovers, Jan, van der Weide
openaire   +2 more sources

Inhibition of CYP2D6 Activity by Bupropion

Journal of Clinical Psychopharmacology, 2005
The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Twenty-one subjects completed this repeated-measures study in which dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching ...
Michael, Kotlyar, Lisa H, Brauer, Timothy S, Tracy, Dorothy K, Hatsukami, Jennifer, Harris, Carrie A, Bronars, David E, Adson   +6 more
openaire   +2 more sources

The Decreased in Vivo Clearance of CYP2D6 Substrates by CYP2D6*10 Might Be Caused Not Only by the Low-Expression but Also by Low Affinity of CYP2D6

Archives of Biochemistry and Biophysics, 2000
CYP2D6 exhibits genetic polymorphism with interindividual differences in metabolic activity. We have found a significant influence on the pharmacokinetics of venlafaxine by the CYP2D6*10 allele in a Japanese population. CYP2D6.10, which is translated from CYP2D6*10, has two amino acid substitutions: Pro34 --> Ser and Ser486 --> Thr.
Tsuyoshi Fukuda, Yuko Nishida, Susumu Imaoka   +2 more
exaly   +3 more sources

Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4

European Journal of Clinical Pharmacology, 1998
After liver transplantation (LT), genotypic differences between the recipient and the transplanted liver, medications and post-LT complications may all affect drug metabolism. We have studied the effect of two CYP2D6 mutations in the donor and the recipient on post-LT CYP2D6 phenotype.The CYP2D6 phenotype was assessed in 48 patients before and after LT
O, Monek, G, Paintaud, Y, Bechtel, J P, Miguet, G, Mantion, P R, Bechtel   +5 more
openaire   +2 more sources

Nomenclature for human CYP2D6 alleles

Pharmacogenetics, 1996
To standardize CYP2D6 allele nomenclature, and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described. Based on recommendations for human genome nomenclature, we propose that alleles be designated by CYP2D6 followed by an asterisk and a combination of roman letters and arabic ...
Daly, A. K., Brockmöller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D. W., Steen, V. M., Wolf, C. R., Zanger, U. M.   +15 more
openaire   +3 more sources